Glomerular disease: Difference between revisions
Line 215: | Line 215: | ||
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Glomerular diseases | ! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Glomerular diseases | ||
! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-entity | ! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Sub-entity | ||
! colspan=" | ! colspan="9" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and Symtoms | ||
! colspan=" | ! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings | ||
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pathology | ! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pathology | ||
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments | ! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Comments | ||
|- | |- | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Hyperlipidemia and hypercholesterolemia | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Hyperlipidemia and hypercholesterolemia | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Auto-antibodies, | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Auto-antibodies, | ||
Complements | Complements | ||
Line 231: | Line 229: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Systemic symptoms | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Systemic symptoms | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hemeturia | |||
!Proteinuria | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hypertension | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Pitting edema | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Pitting edema | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Oliguria | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Oliguria | ||
!Nephrotic features | |||
!Nephritic features | |||
|- | |- | ||
| rowspan="11" align="center" style="background:#4479BA; color: #FFFFFF;" + |Acute Nephritic Syndromes | | rowspan="11" align="center" style="background:#4479BA; color: #FFFFFF;" + |Acute Nephritic Syndromes | ||
Line 247: | Line 248: | ||
* Skin [[rash]] | * Skin [[rash]] | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 272: | Line 274: | ||
* Weight loss | * Weight loss | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 308: | Line 311: | ||
** Easy bruising | ** Easy bruising | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 336: | Line 340: | ||
* [[Anorexia]] | * [[Anorexia]] | ||
* Easy bruising | * Easy bruising | ||
|<nowiki>+</nowiki> | |||
| + | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 341: | Line 347: | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
Line 361: | Line 366: | ||
* Low grade [[fever]] | * Low grade [[fever]] | ||
* [[Flank pain]] | * [[Flank pain]] | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| +/- | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| - | |||
|Immune complex deposition | |Immune complex deposition | ||
| | | | ||
Line 389: | Line 395: | ||
* [[Otitis media]] | * [[Otitis media]] | ||
* [[Epistaxis]]. | * [[Epistaxis]]. | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| + | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| - | |||
|ANCA | |ANCA | ||
| | | | ||
Line 416: | Line 423: | ||
* Neurologic dysfunction | * Neurologic dysfunction | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| + | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| + | | + | ||
| | | | ||
|<nowiki>-</nowiki> | |||
| | | | ||
* [[P-ANCA]] | * [[P-ANCA]] | ||
Line 442: | Line 450: | ||
* [[Peripheral neuropathy]] | * [[Peripheral neuropathy]] | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| + | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | | | ||
|<nowiki>-</nowiki> | |||
| | | | ||
* [[C-ANCA]] | * [[C-ANCA]] | ||
Line 466: | Line 475: | ||
* [[Periorbital edema]] | * [[Periorbital edema]] | ||
* [[Hypertension]] | * [[Hypertension]] | ||
|<nowiki>+</nowiki> | |||
| + | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
Line 484: | Line 494: | ||
! colspan="2" |[[Henoch-Schönlein purpura]] | ! colspan="2" |[[Henoch-Schönlein purpura]] | ||
| | | | ||
* Most common in young male, following upper respiratory infections | * Most common in young male, following [[Upper respiratory tract|upper respiratory]] infections | ||
| | | | ||
* '''Skin manifestations-''' Palpable [[purpura]] on buttocks | * '''Skin manifestations-''' Palpable [[purpura]] on buttocks | ||
Line 494: | Line 504: | ||
* '''Joints''' '''manifestations-''' | * '''Joints''' '''manifestations-''' | ||
** [[Arthralgia]] | ** [[Arthralgia]] | ||
|<nowiki>+</nowiki> | |||
| + | |||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | | | ||
Line 513: | Line 524: | ||
* [[Hepatitis B|Hepatitis B infection]] | * [[Hepatitis B|Hepatitis B infection]] | ||
* Leg ulcers | * Leg ulcers | ||
* Recurrent thrombosis | * Recurrent [[thrombosis]] | ||
|'''Pulmonary symptoms:''' | |'''Pulmonary symptoms:''' | ||
* [[Difficulty breathing]] | * [[Difficulty breathing]] | ||
Line 532: | Line 543: | ||
* [[Diplopia]] | * [[Diplopia]] | ||
* [[Confusion]] | * [[Confusion]] | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
Line 554: | Line 566: | ||
* [[Hodgkin's lymphoma|Hodgkin lymphoma]] | * [[Hodgkin's lymphoma|Hodgkin lymphoma]] | ||
* [[Thrombosis]] (due to [[Urinary system|urinary]] loss of [[Antithrombin III|antithrombin-III]]) | * [[Thrombosis]] (due to [[Urinary system|urinary]] loss of [[Antithrombin III|antithrombin-III]]) | ||
| - | |||
| + | | + | ||
| - | | - | ||
| | | + | ||
| +/- | | +/- | ||
| + | | + | ||
| - | |||
| + | | + | ||
| | | | ||
| | | | ||
Line 578: | Line 591: | ||
* Severe [[obesity]] | * Severe [[obesity]] | ||
* [[Cryoglobulinemia|Mixed cryoglobulinemia]] ([[Hepatitis C]]) | * [[Cryoglobulinemia|Mixed cryoglobulinemia]] ([[Hepatitis C]]) | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
| | | | ||
| | | | ||
Line 600: | Line 614: | ||
* [[Systemic lupus erythematosus]] | * [[Systemic lupus erythematosus]] | ||
* Drugs ([[NSAIDS]], pencilamine, [[gold]], [[captopril]]) | * Drugs ([[NSAIDS]], pencilamine, [[gold]], [[captopril]]) | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
|Immune complex deposition | |Immune complex deposition | ||
| | | | ||
Line 617: | Line 632: | ||
! colspan="2" |[[Diabetic nephropathy|Diabetic Nephropathy]] | ! colspan="2" |[[Diabetic nephropathy|Diabetic Nephropathy]] | ||
| colspan="2" |'''''For more information on diabetes [[Diabetes mellitus|click here]]'''.'' | | colspan="2" |'''''For more information on diabetes [[Diabetes mellitus|click here]]'''.'' | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
| | | | ||
| | | | ||
Line 635: | Line 651: | ||
* Occurs in the setting of high tumor burden | * Occurs in the setting of high tumor burden | ||
| - | | - | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
| - | | - | ||
| | | | ||
Line 665: | Line 682: | ||
* [[Hemorrhagic diathesis|Bleeding tendency]] | * [[Hemorrhagic diathesis|Bleeding tendency]] | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
| - | | - | ||
| | | | ||
Line 686: | Line 703: | ||
| - | | - | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| - | | - | ||
Line 713: | Line 731: | ||
|- | |- | ||
![[Fabry's disease|Fabry's Disease]]<ref name="pmid12068025">{{cite journal |vauthors=Alroy J, Sabnis S, Kopp JB |title=Renal pathology in Fabry disease |journal=J. Am. Soc. Nephrol. |volume=13 Suppl 2 |issue= |pages=S134–8 |date=June 2002 |pmid=12068025 |doi= |url=}}</ref><ref name="pmid9918480">{{cite journal |author=Meikle PJ, Hopwood JJ, Clague AE, Carey WF |title=Prevalence of lysosomal storage disorders |journal=[[JAMA : the Journal of the American Medical Association]] |volume=281 |issue=3 |pages=249–54 |year=1999 |month=January |pmid=9918480 |doi= |url=}}</ref><ref name="pmid11889412">{{cite journal |author=Branton MH, Schiffmann R, Sabnis SG, ''et al.'' |title=Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course |journal=[[Medicine]] |volume=81 |issue=2 |pages=122–38 |year=2002 |month=March |pmid=11889412 |doi= |url=}}</ref> | ![[Fabry's disease|Fabry's Disease]]<ref name="pmid12068025">{{cite journal |vauthors=Alroy J, Sabnis S, Kopp JB |title=Renal pathology in Fabry disease |journal=J. Am. Soc. Nephrol. |volume=13 Suppl 2 |issue= |pages=S134–8 |date=June 2002 |pmid=12068025 |doi= |url=}}</ref><ref name="pmid9918480">{{cite journal |author=Meikle PJ, Hopwood JJ, Clague AE, Carey WF |title=Prevalence of lysosomal storage disorders |journal=[[JAMA : the Journal of the American Medical Association]] |volume=281 |issue=3 |pages=249–54 |year=1999 |month=January |pmid=9918480 |doi= |url=}}</ref><ref name="pmid11889412">{{cite journal |author=Branton MH, Schiffmann R, Sabnis SG, ''et al.'' |title=Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course |journal=[[Medicine]] |volume=81 |issue=2 |pages=122–38 |year=2002 |month=March |pmid=11889412 |doi= |url=}}</ref> | ||
|[[Family history]] suggestive of the disorder | | | ||
* [[Family history]] suggestive of the disorder | |||
| | | | ||
* [[Anhidrosis]] or decreased sweating | * [[Anhidrosis]] or decreased sweating | ||
Line 729: | Line 748: | ||
* [[Telangiectasis]] | * [[Telangiectasis]] | ||
* [[Ataxia]] | * [[Ataxia]] | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
| - | | - | ||
| | | | ||
Line 769: | Line 789: | ||
*Anterior Lenticonus | *Anterior Lenticonus | ||
*Flecked Retinopathy of the Macula or Periphery | *Flecked Retinopathy of the Macula or Periphery | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| + | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| + | | + | ||
|<nowiki>-</nowiki> | |||
| + | | + | ||
| - | | - | ||
| | | | ||
Line 792: | Line 813: | ||
* Positive family history | * Positive family history | ||
* Gross hematuria following upper respiratory tract infection | * Gross [[hematuria]] following [[upper respiratory tract infection]] | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| - | | - | ||
| + | |||
| -/+ | |||
| - | | - | ||
|<nowiki>-/+</nowiki> | |<nowiki>-/+</nowiki> | ||
| - | | - | ||
| -/+ | |||
| - | | - | ||
| - | | - | ||
| - | | - | ||
Line 807: | Line 829: | ||
| | | | ||
|- | |- | ||
! colspan="2" |[[Nail-patella syndrome|Nail-Patella Syndrome]] | ! colspan="2" |[[Nail-patella syndrome|Nail-Patella Syndrome]]<ref name="pmid28941488">{{cite journal |vauthors=Najafian B, Smith K, Lusco MA, Alpers CE, Fogo AB |title=AJKD Atlas of Renal Pathology: Nail-Patella Syndrome-Associated Nephropathy |journal=Am. J. Kidney Dis. |volume=70 |issue=4 |pages=e19–e20 |date=October 2017 |pmid=28941488 |doi=10.1053/j.ajkd.2017.08.001 |url=}}</ref> | ||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
* Positive family history | |||
| | | | ||
* Poorly developed fingernails, toenails, and patellae (kneecaps). | |||
* Elbow deformities | |||
* Abnormally shaped pelvis bone (hip bone) | |||
* [[Knee]] may be small, deformed or absent | |||
|<nowiki>+</nowiki> | |||
| + | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| | | | ||
* Mostly unremarkable changes | |||
* Secondary FSGS | |||
* Late stages: | |||
** Global glomerulosclerosis, | |||
** Tubulointerstitial fibrosis | |||
| | | | ||
| | | | ||
Line 825: | Line 860: | ||
! rowspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular-Vascular Syndromes | ! rowspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular-Vascular Syndromes | ||
! colspan="2" |Atherosclerotic Nephropathy | ! colspan="2" |Atherosclerotic Nephropathy | ||
| | |||
| | | | ||
| | | | ||
Line 841: | Line 877: | ||
|- | |- | ||
! colspan="2" |[[Hypertensive nephropathy|Hypertensive Nephrosclerosis]] | ! colspan="2" |[[Hypertensive nephropathy|Hypertensive Nephrosclerosis]] | ||
| | |||
| | | | ||
| | | | ||
Line 857: | Line 894: | ||
|- | |- | ||
! colspan="2" |[[Cholesterol emboli syndrome|Cholesterol Emboli]] | ! colspan="2" |[[Cholesterol emboli syndrome|Cholesterol Emboli]] | ||
| | |||
| | | | ||
| | | | ||
Line 873: | Line 911: | ||
|- | |- | ||
! colspan="2" |[[Sickle-cell disease|Sickle Cell Disease]] | ! colspan="2" |[[Sickle-cell disease|Sickle Cell Disease]] | ||
| | |||
| | | | ||
| | | | ||
Line 889: | Line 928: | ||
|- | |- | ||
! colspan="2" |[[Thrombotic microangiopathies|Thrombotic Microangiopathies]] | ! colspan="2" |[[Thrombotic microangiopathies|Thrombotic Microangiopathies]] | ||
| | |||
| | | | ||
| | | | ||
Line 905: | Line 945: | ||
|- | |- | ||
! colspan="2" |[[Antiphospholipid syndrome|Antiphospholipid Antibody Syndrome]] | ! colspan="2" |[[Antiphospholipid syndrome|Antiphospholipid Antibody Syndrome]] | ||
| | |||
| | | | ||
| | | | ||
Line 922: | Line 963: | ||
! rowspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + | Infectious Disease–Associated Syndromes | ! rowspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + | Infectious Disease–Associated Syndromes | ||
! colspan="2" |[[Human Immunodeficiency Virus (HIV)|Human Immunodeficiency Virus]] | ! colspan="2" |[[Human Immunodeficiency Virus (HIV)|Human Immunodeficiency Virus]] | ||
| | |||
| | | | ||
| | | | ||
Line 938: | Line 980: | ||
|- | |- | ||
! colspan="2" |[[Hepatitis|Hepatitis B and C]] | ! colspan="2" |[[Hepatitis|Hepatitis B and C]] | ||
| | |||
| | | | ||
| | | | ||
Line 954: | Line 997: | ||
|- | |- | ||
! colspan="2" |Other Viruses | ! colspan="2" |Other Viruses | ||
| | |||
| | | | ||
| | | | ||
Line 970: | Line 1,014: | ||
|- | |- | ||
! colspan="2" |[[Syphilis]] | ! colspan="2" |[[Syphilis]] | ||
| | |||
| | | | ||
| | | | ||
Line 986: | Line 1,031: | ||
|- | |- | ||
! colspan="2" |[[Leprosy]] | ! colspan="2" |[[Leprosy]] | ||
| | |||
| | | | ||
| | | | ||
Line 1,002: | Line 1,048: | ||
|- | |- | ||
! colspan="2" |[[Malaria]] | ! colspan="2" |[[Malaria]] | ||
| | |||
| | | | ||
| | | | ||
Line 1,018: | Line 1,065: | ||
|- | |- | ||
! colspan="2" |[[Schistosomiasis]] | ! colspan="2" |[[Schistosomiasis]] | ||
| | |||
| | | | ||
| | | | ||
Line 1,034: | Line 1,082: | ||
|- | |- | ||
! colspan="2" |Other [[Parasites]] | ! colspan="2" |Other [[Parasites]] | ||
| | |||
| | | | ||
| | | |
Revision as of 19:14, 4 June 2018
This page contains general information about Glomerular disease. For more information on specific types, please visit the pages on nephritic syndrome, nephrotic syndrome, Fabry's disease, amyloidosis, pulmonary-renal syndromes (vasculitis), thin basement membrane disease, Alport's Syndrome, anti-GBM Disease, hypertensive nephrosclerosis, and subacute bacterial endocarditis.
Glomerular disease | |
Acute Glomerulonephritis: Micro H&E high mag; an excellent example of acute exudative glomerulonephritis. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Syed Hassan A. Kazmi BSc, MD [3]
Overview
Glomerular disease is a condition that affects the glomerulus. It consists of different diseases with different clinical courses and treatment options. Glomerular disease can be isolated hematuria, isolated proteinuria; acute or chronic glomerulonephritis, and nephrotic or nephritic features of glomerulonephritis. The end stage of all of these diseases will be glomerulosclerosi swhich is characterized by fibrosis of the glomerulus, and end-stage renal disease.
Classification
Glomerular dieseases can be classified into several clinical and pathological syndromes as below:
Syndrome | Disease |
---|---|
Acute nephritic syndromes |
|
Nephrotic syndrome | |
Glomerular Deposition Diseases |
|
Pulmonary-Renal Syndromes: | |
Basement Membrane Syndromes | |
Glomerular-Vascular Syndromes |
|
Infectious Disease–Associated Syndromes |
Also, glomerular diseases can be classified based on their clinical and urinary pattern in to below types:
Mild nephritc:
This category include mild nephritic sediment that is associated with less than half involvement of glomeruli.
Severe nephritic:
More severe clinical features such as edema, heavy proteinuria, hypertension, and/or renal failure may occur.
Nephrotic:
This syndrome is associated with heavy proteinuria and lipiduria.
Glomerular diseases also may classified by their presentation as below:
Glomerular hematuria:
1- Isolated hematuria
2- Glomerulonephritis (nephritic syndrome)
Proteinuria:
1-Isolated non-nephrotic proteinuria
Rapidly progressive glomerulonephritis
Glomerulonephritis
Glomerulonephritis which is inflammation of the glomeruli can be classified based on pathogenic type into three subtypes:
- Immune complex glomerulonephritis: Granular deposit of immune complex.
- Infection mediated types
- Autoimmune types, eg SLE
- MPGN
- IgA nephropathy (Berger nephropathy)
- Membranous nephropathy
- Anti-GBM disease: Linear deposit
- Goodpasture syndrome (renal and lung involvement)
- Renal involvement alone
- Lung involvement alone
- ANCA associated, small vessels vasculitis: Few or no deposit
Glomerulonephritis (nephritic syndrome) also may be classified based on disease course into acute or chronic nephritic syndrome; primary vs secondary causes; or systemic vs renal limited disease. For more information about nephritic syndrome classifications click here.
Pathophysiology
Microscopic Pathology
-
Glomerulonephritis: Micro H&E med mag; an excellent example of AGN with many neutrophils
-
Acute Glomerulonephritis: Micro H&E high mag; an excellent example of acute exudative glomerulonephritis.
Glomerulonephritis Videos
Rapidly progressive glomerulonephritis
{{#ev:youtube|CqSyj4cVZPE}}
Chronic glomerulonephritis
{{#ev:youtube|eA1vYarRAWo}}
Images
-
This is a low-power photomicrograph of a saggital section of end stage chronic glomerulonephritis (GN). Note the marked thinning of the cortex (arrow).
-
This is a higher-power photomicrograph of hyalinized glomeruli (arrows) and glomeruli with thick basement membranes.
-
This is a higher-power photomicrograph of hyalinized glomeruli (1) and glomeruli with thickened basement membranes (2).
-
This is a photomicrograph of interstitial and vascular lesions in end stage renal disease.
-
This is an immunofluorescent photomicrograph of granular membranous immunofluorescence (immune complex disease). The antibody used for these studies was specific for IgG.
-
This is an electron micrograph of subepithelial granular electron dense deposits (arrows) which correspond to the granular immunofluorescence seen in the previous image.
-
This is a photomicrograph of a glomerulus from another case with acute poststreptococcal glomerulonephritis. In this case the immune complex glomerular disease is ongoing with necrosis and accumulation of neutrophils in the glomerulus.
-
This immunofluorescent photomicrograph of a glomerulus from a case of acute poststreptococcal glomerulonephritis shows a granular immunofluorescence pattern consistent with immune complex disease. The primary antibody used for this staining was specific for IgG; however antibodies for complement would show a similar pattern.
-
This electron micrograph demonstrates scattered subepithelial dense deposits (arrows) and a polymorphonuclear leukocyte in the lumen.
-
For comparison this is an immunofluorescent photomicrograph of a glomerulus from a patient with Goodpasture's syndrome. The linear (arrows) immunofluorescence is characteristic of Goodpasture's syndrome.
Images:
Differential Diagnosis
Glomerulonephritis may be proliferative or non-proliferative and may be associated with nephrotic or nephritic features. The various types of glomerulonephritides should be differentiated from each other based on associations, presence of pitting edema, hemeturia, hypertension, hemoptysis, oliguria, peri-orbital edema, hyperlipidemia, type of antibodies, light and electron microscopic features. The following table differentiates between various types of glomerulonephritides:[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]
Glomerular diseases | Sub-entity | History and Symtoms | Laboratory Findings | Pathology | Comments | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hyperlipidemia and hypercholesterolemia | Auto-antibodies,
Complements |
Light microscope | Electron microscope | Immunoflourescence pattern | |||||||||||||
History | Systemic symptoms | Hemeturia | Proteinuria | Hypertension | Pitting edema | Oliguria | Nephrotic features | Nephritic features | |||||||||
Acute Nephritic Syndromes | Poststreptococcal Glomerulonephritis |
|
+/- | + | +/- | +/- | +/- | +/- | +/- | +/- |
|
Hypercellular and inflamed glomeruli
|
Immune complex GN, granular deposit | Pathologic involvement correlates with the clinical findings | |||
Renal disease due to Subacute Bacterial Endocarditis, or cardiac shunt (Atrioventricular) |
|
+/- | + | +/- | +/- | +/- | +/- | +/- | +/- |
|
|
|
|
||||
Lupus Nephritis |
|
|
+/- | + | +/- | +/- | +/- | +/- | +/- | +/- |
|
Differs based on the disease classification | Differs based on the disease classification | Differs based on the disease classification, mostly immune complex GN, granular deposit | Disease presentation is different based on lupus nephritis classifications | ||
Antiglomerular Basement Membrane Disease (Goodpasture's syndrome) |
|
|
+ | + | + | + | + | + | - | - |
|
Immune complex GN, Linear deposit | |||||
IgA Nephropathy |
|
|
+ | +/- | + | +/- | + | - | + | - | Immune complex deposition |
|
|
Immune complex GN, granular deposite | |||
ANCA Small-Vessel Vasculitis | Granulomatosis with Polyangiitis (Wegener's) |
|
|
+ | + | + | +/- | + | - | + | - | ANCA |
|
|
Pauci-immune GN | ||
Microscopic Polyangiitis | +/- |
|
+ | + | + | + | + | + | - | - | Pauci-immune GN | ||||||
Churg-Strauss Syndrome | +/- | + | + | + | + | + | + | - | Hypercellular and inflamed glomeruli (Crescent formation)-
(pauci-immune) |
- | Pauci-immune GN | ||||||
Membranoproliferative Glomerulonephritis |
|
+ | + | + | +/- | + | + | - | - |
|
|
Immune complex GN, granular deposite | |||||
Henoch-Schönlein purpura |
|
|
+ | + | + | +/- | + | + | - | - |
|
Immune complex GN, granular deposite | |||||
Cryoglobulinemia | Patients having cryoglobulinemia may have positive history of:
|
Pulmonary symptoms:
Cutaneous symptoms: Gastrointestinal symptoms:
General symptoms:
|
+/- | + | +/- | + | +/- | +/- | +/- | +/- | +/- | ||||||
Nephrotic Syndrome | Minimal Change Disease |
|
- | + | - | + | +/- | + | - | + |
|
|
- | ||||
Focal Segmental Glomerulosclerosis |
|
- | + | - | + | +/- | + | - | + |
|
|
- | |||||
Membranous Glomerulonephritis |
|
- | + | - | + | +/- | + | - | + | Immune complex deposition |
|
Immune complex GN, granular deposite | |||||
Diabetic Nephropathy | For more information on diabetes click here. | - | + | - | + | +/- | + | - | + | ||||||||
Glomerular Deposition Diseases | Light Chain Deposition Disease[25] |
|
- | - | + | - | + | +/- | + | - | + | - |
|
|
|
| |
Renal Amyloidosis[26][27][28][29] |
|
- | + | - | + | +/- | + | - | + | - | |||||||
Fibrillary-Immunotactoid Glomerulopathy[30] | - | +/- | + | +/- | +/- | +/- | + | +/- | +/- | - |
|
|
|
||||
Fabry's Disease[31][32][33] |
|
|
- | + | - | + | +/- | + | - | + | - |
|
|
- | - | ||
Basement Membrane Syndrome | Alport's Syndrome[34][35][36][37][38][39] |
|
Auditary:
Occular problems:
|
- | + | - | + | +/- | + | - | + | - |
|
|
|
- | |
Thin Basement Membrane Disease |
|
- | - | + | -/+ | - | -/+ | - | -/+ | - | - | - | Diffuse thinning of the glomerular basement membranes (GBM) | - | |||
Nail-Patella Syndrome[40] |
|
|
+ | + | - | - | - | - | - | - | - |
|
|||||
Glomerular-Vascular Syndromes | Atherosclerotic Nephropathy | ||||||||||||||||
Hypertensive Nephrosclerosis | |||||||||||||||||
Cholesterol Emboli | |||||||||||||||||
Sickle Cell Disease | |||||||||||||||||
Thrombotic Microangiopathies | |||||||||||||||||
Antiphospholipid Antibody Syndrome | |||||||||||||||||
Infectious Disease–Associated Syndromes | Human Immunodeficiency Virus | ||||||||||||||||
Hepatitis B and C | |||||||||||||||||
Other Viruses | |||||||||||||||||
Syphilis | |||||||||||||||||
Leprosy | |||||||||||||||||
Malaria | |||||||||||||||||
Schistosomiasis | |||||||||||||||||
Other Parasites |
References
- ↑ Saha TC, Singh H (November 2006). "Minimal change disease: a review". South. Med. J. 99 (11): 1264–70. doi:10.1097/01.smj.0000243183.87381.c2. PMID 17195422.
- ↑ Saleem MA, Kobayashi Y (2016). "Cell biology and genetics of minimal change disease". F1000Res. 5. doi:10.12688/f1000research.7300.1. PMC 4821284. PMID 27092244.
- ↑ Keskar V, Jamale TE, Kulkarni MJ, Kiggal Jagadish P, Fernandes G, Hase N (October 2013). "Minimal-change disease in adolescents and adults: epidemiology and therapeutic response". Clin Kidney J. 6 (5): 469–72. doi:10.1093/ckj/sft063. PMC 4438390. PMID 26064510.
- ↑ Chugh SS, Clement LC, Macé C (February 2012). "New insights into human minimal change disease: lessons from animal models". Am. J. Kidney Dis. 59 (2): 284–92. doi:10.1053/j.ajkd.2011.07.024. PMC 3253318. PMID 21974967.
- ↑ Rosenberg AZ, Kopp JB (March 2017). "Focal Segmental Glomerulosclerosis". Clin J Am Soc Nephrol. 12 (3): 502–517. doi:10.2215/CJN.05960616. PMC 5338705. PMID 28242845.
- ↑ Jefferson JA, Shankland SJ (September 2014). "The pathogenesis of focal segmental glomerulosclerosis". Adv Chronic Kidney Dis. 21 (5): 408–16. doi:10.1053/j.ackd.2014.05.009. PMC 4149756. PMID 25168829.
- ↑ Gephardt GN, Tubbs RR, Popowniak KL, McMahon JT (October 1986). "Focal and segmental glomerulosclerosis. Immunohistologic study of 20 renal biopsy specimens". Arch. Pathol. Lab. Med. 110 (10): 902–5. PMID 2429634.
- ↑ Lai WL, Yeh TH, Chen PM, Chan CK, Chiang WC, Chen YM, Wu KD, Tsai TJ (February 2015). "Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment". J. Formos. Med. Assoc. 114 (2): 102–11. doi:10.1016/j.jfma.2014.11.002. PMID 25558821.
- ↑ Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
- ↑ Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (October 2011). "The pathophysiology of IgA nephropathy". J. Am. Soc. Nephrol. 22 (10): 1795–803. doi:10.1681/ASN.2011050464. PMC 3892742. PMID 21949093.
- ↑ Wyatt RJ, Julian BA (June 2013). "IgA nephropathy". N. Engl. J. Med. 368 (25): 2402–14. doi:10.1056/NEJMra1206793. PMID 23782179.
- ↑ He S, Wu Z (November 2011). "Gene-based Higher Criticism methods for large-scale exonic single-nucleotide polymorphism data". BMC Proc. 5 Suppl 9: S65. doi:10.1186/1753-6561-5-S9-S65. PMC 3287904. PMID 22373436.
- ↑ Higgins RM, Goldsmith DJ, Connolly J, Scoble JE, Hendry BM, Ackrill P, Venning MC (January 1996). "Vasculitis and rapidly progressive glomerulonephritis in the elderly". Postgrad Med J. 72 (843): 41–4. PMC 2398323. PMID 8746284.
- ↑ Jennette JC (March 2003). "Rapidly progressive crescentic glomerulonephritis". Kidney Int. 63 (3): 1164–77. doi:10.1046/j.1523-1755.2003.00843.x. PMID 12631105.
- ↑ Bolton WK (November 1996). "Goodpasture's syndrome". Kidney Int. 50 (5): 1753–66. PMID 8914046.
- ↑ Mathew TH, Hobbs JB, Kalowski S, Sutherland PW, Kincaid-Smith P (February 1975). "Goodpasture's syndrome: normal renal diagnostic findings". Ann. Intern. Med. 82 (2): 215–8. PMID 1090223.
- ↑ Renaudineau Y, Le Meur Y (October 2008). "Renal involvement in Wegener's granulomatosis". Clin Rev Allergy Immunol. 35 (1–2): 22–9. doi:10.1007/s12016-007-8066-6. PMID 18172777.
- ↑ Weiss MA, Crissman JD (October 1984). "Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis". Hum. Pathol. 15 (10): 943–56. PMID 6384024.
- ↑ Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, Giammarresi G, Tumiati B, Gregorini G, Pesci A, Monti S, Balestrieri G, Garini G, Vecchio F, Buzio C (May 2006). "Renal involvement in Churg-Strauss syndrome". Am. J. Kidney Dis. 47 (5): 770–9. doi:10.1053/j.ajkd.2006.01.026. PMID 16632015.
- ↑ Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC (September 2011). "Rituximab for the treatment of Churg-Strauss syndrome with renal involvement". Nephrol. Dial. Transplant. 26 (9): 2865–71. doi:10.1093/ndt/gfq852. PMC 3218640. PMID 21325353.
- ↑ Chung SA, Seo P (August 2010). "Microscopic polyangiitis". Rheum. Dis. Clin. North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
- ↑ Pagnoux C (March 2008). "[Wegener's granulomatosis and microscopic polyangiitis]". Rev Prat (in French). 58 (5): 522–32. PMID 18524109.
- ↑ Alchi B, Jayne D (August 2010). "Membranoproliferative glomerulonephritis". Pediatr. Nephrol. 25 (8): 1409–18. doi:10.1007/s00467-009-1322-7. PMC 2887509. PMID 19908070.
- ↑ Davis AE, Schneeberger EE, Grupe WE, McCluskey RT (May 1978). "Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children". Clin. Nephrol. 9 (5): 184–93. PMID 657595.
- ↑ Hutchison CA, Cockwell P, Stringer S, Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S, Rajkumar SV, Kyle RA, Leung N (June 2011). "Early reduction of serum-free light chains associates with renal recovery in myeloma kidney". J. Am. Soc. Nephrol. 22 (6): 1129–36. doi:10.1681/ASN.2010080857. PMC 3103732. PMID 21511832.
- ↑ Baker KR, Rice L (2012). "The amyloidoses: clinical features, diagnosis and treatment". Methodist Debakey Cardiovasc J. 8 (3): 3–7. PMC 3487569. PMID 23227278.
- ↑ Gillmore JD, Hawkins PN (October 2013). "Pathophysiology and treatment of systemic amyloidosis". Nat Rev Nephrol. 9 (10): 574–86. doi:10.1038/nrneph.2013.171. PMID 23979488.
- ↑ Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA (2014). "Primary systemic amyloidosis as a real diagnostic challenge - case study". Cent Eur J Immunol. 39 (1): 61–6. doi:10.5114/ceji.2014.42126. PMC 4439975. PMID 26155101.
- ↑ Pepys MB (2006). "Amyloidosis". Annu. Rev. Med. 57: 223–41. doi:10.1146/annurev.med.57.121304.131243. PMID 16409147.
- ↑ Korbet SM, Schwartz MM, Lewis EJ (March 1991). "Immunotactoid glomerulopathy". Am. J. Kidney Dis. 17 (3): 247–57. PMID 1996564.
- ↑ Alroy J, Sabnis S, Kopp JB (June 2002). "Renal pathology in Fabry disease". J. Am. Soc. Nephrol. 13 Suppl 2: S134–8. PMID 12068025.
- ↑ Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999). "Prevalence of lysosomal storage disorders". JAMA : the Journal of the American Medical Association. 281 (3): 249–54. PMID 9918480. Unknown parameter
|month=
ignored (help) - ↑ Branton MH, Schiffmann R, Sabnis SG; et al. (2002). "Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course". Medicine. 81 (2): 122–38. PMID 11889412. Unknown parameter
|month=
ignored (help) - ↑ McCarthy PA, Maino DM (2000). "Alport syndrome: a review". Clin Eye Vis Care. 12 (3–4): 139–150. PMID 11137428.
- ↑ Chugh KS, Sakhuja V, Agarwal A, Jha V, Joshi K, Datta BN; et al. (1993). "Hereditary nephritis (Alport's syndrome)--clinical profile and inheritance in 28 kindreds". Nephrol Dial Transplant. 8 (8): 690–5. PMID 8414153.
- ↑ Chugh KS, Sakhuja V, Agarwal A, Jha V, Joshi K, Datta BN; et al. (1993). "Hereditary nephritis (Alport's syndrome)--clinical profile and inheritance in 28 kindreds". Nephrol Dial Transplant. 8 (8): 690–5. PMID 8414153.
- ↑ McCarthy PA, Maino DM (2000). "Alport syndrome: a review". Clin Eye Vis Care. 12 (3–4): 139–150. PMID 11137428.
- ↑ Amari F, Segawa K, Ando F (1994). "Lens coloboma and Alport-like glomerulonephritis". Eur J Ophthalmol. 4 (3): 181–3. PMID 7819734.
- ↑ Govan JA (1983). "Ocular manifestations of Alport's syndrome: a hereditary disorder of basement membranes?". Br J Ophthalmol. 67 (8): 493–503. PMC 1040106. PMID 6871140.
- ↑ Najafian B, Smith K, Lusco MA, Alpers CE, Fogo AB (October 2017). "AJKD Atlas of Renal Pathology: Nail-Patella Syndrome-Associated Nephropathy". Am. J. Kidney Dis. 70 (4): e19–e20. doi:10.1053/j.ajkd.2017.08.001. PMID 28941488.